Merck is in advanced talks to buy Seagen in a nearly $40 billion deal 🤝
🔸 Drugmaker $MRK (Merck & Co.) is reportedly in advanced talks to buy cancer-focused biotech company $SGEN (Seagen Inc) in a deal worth roughly $40 billion or more. The companies would be discussing a price above $200 a share... Afficher plus Traduction
